Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Tscan Therapeutics Inc
TCRXCurrent price
4.82 USD
-0.48 USD (-9.06%)
Last closed
5.25 USD
Company
www.tscan.com
ISIN
US89854M1018
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
306 189 152 USD
Yield for 12 month
+1.26 %
1Y
3Y
5Y
10Y
15Y
TCRX
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Address: 830 Winter Street, Waltham, MA, United States, 02451
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
12.57 USDP/E ratio
–Dividend Yield
–Current Year
+21 049 000 USD
Last Year
+13 535 000 USD
Current Quarter
+536 000 USD
Last Quarter
+566 000 USD
Current Year
+15 688 000 USD
Last Year
+8 398 000 USD
Current Quarter
-580 000 USD
Last Quarter
-688 000 USD
Key Figures TCRX
1 year
3 years
5 years
10 years
EBITDA
-106 656 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-20.16 %
PEG Ratio
–
Return On Equity TTM
-46.84 %
Wall Street Target Price
12.57 USD
Revenue TTM
12 200 000 USD
Book Value
4.82 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-83 %
Dividend Yield
–
Gross Profit TTM
-46 284 000 USD
Earnings per share
-0.65 USD
Diluted Eps TTM
-0.65 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics TCRX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TCRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation TCRX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
8.1628
Price Sales TTM
25.0975
Enterprise Value EBITDA
0.3916
Price Book MRQ
1.1997
Financials TCRX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TCRX
For 52 weeks
3.73 USD
9.69 USD
50 Day MA
5.35 USD
Shares Short Prior Month
2 065 654
200 Day MA
6.62 USD
Short Ratio
10.64
Shares Short
2 244 117
Short Percent
5.87 %
BeatStart